Global Antisense Therapy Market
Global Antisense Therapy Market

Antisense Therapy Comprehensive Study by Route of Administration (Pulmonary Delivery, Intravenous Injections, Intra-dermal Injections, Intraperitoneal injections, Topical Delivery, Other), End-users (Hospitals, Research Institutes, Others), Indication (Oncology, Cardiovascular Diseases, Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other) Players and Region - Global Market Outlook to 2027

Antisense Therapy Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

Feb 2022 Edition 243 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Antisense Therapy?
Antisense remedy is an strategy to conflict ailments the use of quick DNA-like molecules known as antisense oligonucleotides. Recently, antisense remedy has emerged as an thrilling and promising approach for the cure of a range of neurodegenerative and neuromuscular disorders. Antisense remedy includes downregulation of gene expression by means of complementary oligonucleotide binding to goal mRNA. Antisense oligonucleotides are quick single-stranded DNA sequences engineered to be complementary to the particular ‘sense’ (5' to 3') orientation of mRNA coding for the focused protein.

The market study is broken down and major geographies with country level break-up.

The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing towards the production technologies, efficiency enhancement and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge invest in market growth strategies. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Antisense Therapy market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline Plc (United Kingdom), Bio-Path Holdings Inc. (United States), Calando Pharmaceuticals (United States), Ionis Pharmaceuticals (United States), Enzon Pharmaceuticals Inc (United States), Gradalis (United States), Sanofi S.A (France), miRagen Therapeutics (United States), Olix Pharmaceuticals (South Korea) and OncoGeneX Pharmaceuticals (Canada) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Regulus Therapeutics (United States), Rexahn Pharmaceuticals (United States), Rxi Pharmaceuticals (United States) and Santaris Pharma A/S (Roche) (Denmark).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Antisense Therapy market by Type, Application and Region.

On the basis of geography, the market of Antisense Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Pulmonary Delivery will boost the Antisense Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-users, the sub-segment i.e. Hospitals will boost the Antisense Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Indication, the sub-segment i.e. Oncology will boost the Antisense Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In 2022, Pfizer Inc. and Ionis Pharmaceuticals, Inc. announced the discontinuation of the Pfizer-led clinical development program for vupanorsen (PF-07285557), an investigational antisense therapy that was being evaluated for potential indications in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG).


Market Trend
  • Increase in Prevalence of Chronic Disease along with rise in Elderly Population

Market Drivers
  • Rise in the Prevalence Diseases such as Cancer, Cardiovascular Disorders and Others

Opportunities
  • Rising Research activities in Gene Therapy, Immunotherapy & Cell Therapy Treatments
  • Rising Healthcare Expenditure

Restraints
  • High Cost Associated with of RNA Interference-based Drugs

Challenges
  • Stringent Regulations, and Long Product Approval Process


Key Target Audience
Venture Capitalists and Private Equity Firms, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Frequently Asked Questions (FAQ):

1. What all players are profiled in the study?
The standard version of the report profiles players such as GlaxoSmithKline Plc (United Kingdom), Bio-Path Holdings Inc. (United States), Calando Pharmaceuticals (United States), Ionis Pharmaceuticals (United States), Enzon Pharmaceuticals Inc (United States), Gradalis (United States), Sanofi S.A (France), miRagen Therapeutics (United States), Olix Pharmaceuticals (South Korea) and OncoGeneX Pharmaceuticals (Canada) etc.

2. Can we have customized study for Antisense Therapy Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. What would be the Market Size of Antisense Therapy Market by 2027?
Analysts at AMA estimates Antisense Therapy Market to reach USD Million by 2027.
Report Objectives / Segmentation Covered
By Route of Administration
  • Pulmonary Delivery
  • Intravenous Injections
  • Intra-dermal Injections
  • Intraperitoneal injections
  • Topical Delivery
  • Other

By End-users
  • Hospitals
  • Research Institutes
  • Others

By Indication
  • Oncology
  • Cardiovascular Diseases
  • Respiratory Disorders
  • Neurological Disorders
  • Infectious Diseases
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in the Prevalence Diseases such as Cancer, Cardiovascular Disorders and Others
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulations, and Long Product Approval Process
    • 3.4. Market Trends
      • 3.4.1. Increase in Prevalence of Chronic Disease along with rise in Elderly Population
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antisense Therapy, by Route of Administration, End-users, Indication and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Antisense Therapy (Value)
      • 5.2.1. Global Antisense Therapy by: Route of Administration (Value)
        • 5.2.1.1. Pulmonary Delivery
        • 5.2.1.2. Intravenous Injections
        • 5.2.1.3. Intra-dermal Injections
        • 5.2.1.4. Intraperitoneal injections
        • 5.2.1.5. Topical Delivery
        • 5.2.1.6. Other
      • 5.2.2. Global Antisense Therapy by: End-users (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Research Institutes
        • 5.2.2.3. Others
      • 5.2.3. Global Antisense Therapy by: Indication (Value)
        • 5.2.3.1. Oncology
        • 5.2.3.2. Cardiovascular Diseases
        • 5.2.3.3. Respiratory Disorders
        • 5.2.3.4. Neurological Disorders
        • 5.2.3.5. Infectious Diseases
        • 5.2.3.6. Other
      • 5.2.4. Global Antisense Therapy Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Antisense Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bio-Path Holdings Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Calando Pharmaceuticals (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Ionis Pharmaceuticals (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Enzon Pharmaceuticals Inc (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Gradalis (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi S.A (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. MiRagen Therapeutics (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Olix Pharmaceuticals (South Korea)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. OncoGeneX Pharmaceuticals (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Antisense Therapy Sale, by Route of Administration, End-users, Indication and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Antisense Therapy (Value)
      • 7.2.1. Global Antisense Therapy by: Route of Administration (Value)
        • 7.2.1.1. Pulmonary Delivery
        • 7.2.1.2. Intravenous Injections
        • 7.2.1.3. Intra-dermal Injections
        • 7.2.1.4. Intraperitoneal injections
        • 7.2.1.5. Topical Delivery
        • 7.2.1.6. Other
      • 7.2.2. Global Antisense Therapy by: End-users (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Research Institutes
        • 7.2.2.3. Others
      • 7.2.3. Global Antisense Therapy by: Indication (Value)
        • 7.2.3.1. Oncology
        • 7.2.3.2. Cardiovascular Diseases
        • 7.2.3.3. Respiratory Disorders
        • 7.2.3.4. Neurological Disorders
        • 7.2.3.5. Infectious Diseases
        • 7.2.3.6. Other
      • 7.2.4. Global Antisense Therapy Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antisense Therapy: by Route of Administration(USD Million)
  • Table 2. Antisense Therapy Pulmonary Delivery , by Region USD Million (2016-2021)
  • Table 3. Antisense Therapy Intravenous Injections , by Region USD Million (2016-2021)
  • Table 4. Antisense Therapy Intra-dermal Injections , by Region USD Million (2016-2021)
  • Table 5. Antisense Therapy Intraperitoneal injections , by Region USD Million (2016-2021)
  • Table 6. Antisense Therapy Topical Delivery , by Region USD Million (2016-2021)
  • Table 7. Antisense Therapy Other , by Region USD Million (2016-2021)
  • Table 8. Antisense Therapy: by End-users(USD Million)
  • Table 9. Antisense Therapy Hospitals , by Region USD Million (2016-2021)
  • Table 10. Antisense Therapy Research Institutes , by Region USD Million (2016-2021)
  • Table 11. Antisense Therapy Others , by Region USD Million (2016-2021)
  • Table 12. Antisense Therapy: by Indication(USD Million)
  • Table 13. Antisense Therapy Oncology , by Region USD Million (2016-2021)
  • Table 14. Antisense Therapy Cardiovascular Diseases , by Region USD Million (2016-2021)
  • Table 15. Antisense Therapy Respiratory Disorders , by Region USD Million (2016-2021)
  • Table 16. Antisense Therapy Neurological Disorders , by Region USD Million (2016-2021)
  • Table 17. Antisense Therapy Infectious Diseases , by Region USD Million (2016-2021)
  • Table 18. Antisense Therapy Other , by Region USD Million (2016-2021)
  • Table 19. South America Antisense Therapy, by Country USD Million (2016-2021)
  • Table 20. South America Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 21. South America Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 22. South America Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 23. Brazil Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 24. Brazil Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 25. Brazil Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 26. Argentina Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 27. Argentina Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 28. Argentina Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 29. Rest of South America Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 30. Rest of South America Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 31. Rest of South America Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 32. Asia Pacific Antisense Therapy, by Country USD Million (2016-2021)
  • Table 33. Asia Pacific Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 34. Asia Pacific Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 35. Asia Pacific Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 36. China Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 37. China Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 38. China Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 39. Japan Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 40. Japan Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 41. Japan Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 42. India Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 43. India Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 44. India Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 45. South Korea Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 46. South Korea Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 47. South Korea Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 48. Taiwan Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 49. Taiwan Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 50. Taiwan Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 51. Australia Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 52. Australia Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 53. Australia Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 54. Rest of Asia-Pacific Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 55. Rest of Asia-Pacific Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 56. Rest of Asia-Pacific Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 57. Europe Antisense Therapy, by Country USD Million (2016-2021)
  • Table 58. Europe Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 59. Europe Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 60. Europe Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 61. Germany Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 62. Germany Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 63. Germany Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 64. France Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 65. France Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 66. France Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 67. Italy Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 68. Italy Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 69. Italy Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 70. United Kingdom Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 71. United Kingdom Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 72. United Kingdom Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 73. Netherlands Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 74. Netherlands Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 75. Netherlands Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 76. Rest of Europe Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 77. Rest of Europe Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 78. Rest of Europe Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 79. MEA Antisense Therapy, by Country USD Million (2016-2021)
  • Table 80. MEA Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 81. MEA Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 82. MEA Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 83. Middle East Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 84. Middle East Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 85. Middle East Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 86. Africa Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 87. Africa Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 88. Africa Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 89. North America Antisense Therapy, by Country USD Million (2016-2021)
  • Table 90. North America Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 91. North America Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 92. North America Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 93. United States Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 94. United States Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 95. United States Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 96. Canada Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 97. Canada Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 98. Canada Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 99. Mexico Antisense Therapy, by Route of Administration USD Million (2016-2021)
  • Table 100. Mexico Antisense Therapy, by End-users USD Million (2016-2021)
  • Table 101. Mexico Antisense Therapy, by Indication USD Million (2016-2021)
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Antisense Therapy: by Route of Administration(USD Million)
  • Table 113. Antisense Therapy Pulmonary Delivery , by Region USD Million (2022-2027)
  • Table 114. Antisense Therapy Intravenous Injections , by Region USD Million (2022-2027)
  • Table 115. Antisense Therapy Intra-dermal Injections , by Region USD Million (2022-2027)
  • Table 116. Antisense Therapy Intraperitoneal injections , by Region USD Million (2022-2027)
  • Table 117. Antisense Therapy Topical Delivery , by Region USD Million (2022-2027)
  • Table 118. Antisense Therapy Other , by Region USD Million (2022-2027)
  • Table 119. Antisense Therapy: by End-users(USD Million)
  • Table 120. Antisense Therapy Hospitals , by Region USD Million (2022-2027)
  • Table 121. Antisense Therapy Research Institutes , by Region USD Million (2022-2027)
  • Table 122. Antisense Therapy Others , by Region USD Million (2022-2027)
  • Table 123. Antisense Therapy: by Indication(USD Million)
  • Table 124. Antisense Therapy Oncology , by Region USD Million (2022-2027)
  • Table 125. Antisense Therapy Cardiovascular Diseases , by Region USD Million (2022-2027)
  • Table 126. Antisense Therapy Respiratory Disorders , by Region USD Million (2022-2027)
  • Table 127. Antisense Therapy Neurological Disorders , by Region USD Million (2022-2027)
  • Table 128. Antisense Therapy Infectious Diseases , by Region USD Million (2022-2027)
  • Table 129. Antisense Therapy Other , by Region USD Million (2022-2027)
  • Table 130. South America Antisense Therapy, by Country USD Million (2022-2027)
  • Table 131. South America Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 132. South America Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 133. South America Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 134. Brazil Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 135. Brazil Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 136. Brazil Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 137. Argentina Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 138. Argentina Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 139. Argentina Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 140. Rest of South America Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 141. Rest of South America Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 142. Rest of South America Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 143. Asia Pacific Antisense Therapy, by Country USD Million (2022-2027)
  • Table 144. Asia Pacific Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 145. Asia Pacific Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 146. Asia Pacific Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 147. China Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 148. China Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 149. China Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 150. Japan Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 151. Japan Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 152. Japan Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 153. India Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 154. India Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 155. India Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 156. South Korea Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 157. South Korea Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 158. South Korea Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 159. Taiwan Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 160. Taiwan Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 161. Taiwan Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 162. Australia Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 163. Australia Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 164. Australia Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 165. Rest of Asia-Pacific Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 166. Rest of Asia-Pacific Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 167. Rest of Asia-Pacific Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 168. Europe Antisense Therapy, by Country USD Million (2022-2027)
  • Table 169. Europe Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 170. Europe Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 171. Europe Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 172. Germany Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 173. Germany Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 174. Germany Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 175. France Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 176. France Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 177. France Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 178. Italy Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 179. Italy Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 180. Italy Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 181. United Kingdom Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 182. United Kingdom Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 183. United Kingdom Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 184. Netherlands Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 185. Netherlands Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 186. Netherlands Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 187. Rest of Europe Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 188. Rest of Europe Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 189. Rest of Europe Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 190. MEA Antisense Therapy, by Country USD Million (2022-2027)
  • Table 191. MEA Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 192. MEA Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 193. MEA Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 194. Middle East Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 195. Middle East Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 196. Middle East Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 197. Africa Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 198. Africa Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 199. Africa Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 200. North America Antisense Therapy, by Country USD Million (2022-2027)
  • Table 201. North America Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 202. North America Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 203. North America Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 204. United States Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 205. United States Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 206. United States Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 207. Canada Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 208. Canada Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 209. Canada Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 210. Mexico Antisense Therapy, by Route of Administration USD Million (2022-2027)
  • Table 211. Mexico Antisense Therapy, by End-users USD Million (2022-2027)
  • Table 212. Mexico Antisense Therapy, by Indication USD Million (2022-2027)
  • Table 213. Research Programs/Design for This Report
  • Table 214. Key Data Information from Secondary Sources
  • Table 215. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antisense Therapy: by Route of Administration USD Million (2016-2021)
  • Figure 5. Global Antisense Therapy: by End-users USD Million (2016-2021)
  • Figure 6. Global Antisense Therapy: by Indication USD Million (2016-2021)
  • Figure 7. South America Antisense Therapy Share (%), by Country
  • Figure 8. Asia Pacific Antisense Therapy Share (%), by Country
  • Figure 9. Europe Antisense Therapy Share (%), by Country
  • Figure 10. MEA Antisense Therapy Share (%), by Country
  • Figure 11. North America Antisense Therapy Share (%), by Country
  • Figure 12. Global Antisense Therapy share by Players 2021 (%)
  • Figure 13. Global Antisense Therapy share by Players (Top 3) 2021(%)
  • Figure 14. Global Antisense Therapy share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2021
  • Figure 18. Bio-Path Holdings Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Bio-Path Holdings Inc. (United States) Revenue: by Geography 2021
  • Figure 20. Calando Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 21. Calando Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 22. Ionis Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 23. Ionis Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 24. Enzon Pharmaceuticals Inc (United States) Revenue, Net Income and Gross profit
  • Figure 25. Enzon Pharmaceuticals Inc (United States) Revenue: by Geography 2021
  • Figure 26. Gradalis (United States) Revenue, Net Income and Gross profit
  • Figure 27. Gradalis (United States) Revenue: by Geography 2021
  • Figure 28. Sanofi S.A (France) Revenue, Net Income and Gross profit
  • Figure 29. Sanofi S.A (France) Revenue: by Geography 2021
  • Figure 30. MiRagen Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 31. MiRagen Therapeutics (United States) Revenue: by Geography 2021
  • Figure 32. Olix Pharmaceuticals (South Korea) Revenue, Net Income and Gross profit
  • Figure 33. Olix Pharmaceuticals (South Korea) Revenue: by Geography 2021
  • Figure 34. OncoGeneX Pharmaceuticals (Canada) Revenue, Net Income and Gross profit
  • Figure 35. OncoGeneX Pharmaceuticals (Canada) Revenue: by Geography 2021
  • Figure 36. Global Antisense Therapy: by Route of Administration USD Million (2022-2027)
  • Figure 37. Global Antisense Therapy: by End-users USD Million (2022-2027)
  • Figure 38. Global Antisense Therapy: by Indication USD Million (2022-2027)
  • Figure 39. South America Antisense Therapy Share (%), by Country
  • Figure 40. Asia Pacific Antisense Therapy Share (%), by Country
  • Figure 41. Europe Antisense Therapy Share (%), by Country
  • Figure 42. MEA Antisense Therapy Share (%), by Country
  • Figure 43. North America Antisense Therapy Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • GlaxoSmithKline Plc (United Kingdom)
  • Bio-Path Holdings Inc. (United States)
  • Calando Pharmaceuticals (United States)
  • Ionis Pharmaceuticals (United States)
  • Enzon Pharmaceuticals Inc (United States)
  • Gradalis (United States)
  • Sanofi S.A (France)
  • miRagen Therapeutics (United States)
  • Olix Pharmaceuticals (South Korea)
  • OncoGeneX Pharmaceuticals (Canada)
Additional players considered in the study are as follows:
Regulus Therapeutics (United States) , Rexahn Pharmaceuticals (United States) , Rxi Pharmaceuticals (United States) , Santaris Pharma A/S (Roche) (Denmark)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation